Qiri does not screen a script with one general model. Six specialist checks reason over it in their own domain, and a pharmacist signs the result. Most scripts need only the pharma specialist. The other five are called in when a script needs them.
Most scripts are screened by this specialist alone. It works the whole medication profile: interaction chains, renal and hepatic dose review, allergy and contraindication checks, LASA risk, and therapeutic duplication.
The whole medication list at once, not one drug pair at a time.
Dose read against the patient's renal and hepatic function, surfaced for the pharmacist to review.
The patient's allergy record against every active script, before supply.
Look-alike, sound-alike pairs caught at entry, not at the shelf.
Two medicines doing one job, flagged before the patient takes both.
Some scripts turn on the patient's metabolism rather than the drug list. Those come here: cytochrome P450 pathways, PK/PD behaviour, pharmacogenomic results, and therapeutic drug monitoring.
Inhibitors, inducers and substrates across the P450 enzyme families.
Genetic results read as poor, intermediate or ultra-rapid metaboliser phenotypes, with high-risk drug-gene pairs flagged against published pharmacogenomic guidelines.
Serum levels, sample timing, and the dose change that follows.
Chemotherapy leaves the least room for error of anything a pharmacy dispenses. This specialist verifies the regimen against protocol, tracks cumulative dose against toxicity ceilings, and flags where a patient sits outside the trial population the guideline was built on.
Regimens against recognised oncology protocol libraries: cycle timing, drug combinations, pre-medications.
Tumour type, stage, body surface area, and organ function.
Lifetime dose against known ceilings, such as anthracycline cardiotoxicity and platinum nephrotoxicity.
Anti-emetic, growth factor and prophylactic cover matched to the cycle.
Pharmacy answers to a medicines regulator, a subsidy scheme, and controlled-substance schedules that vary by jurisdiction. This specialist puts them in front of the pharmacist before a supply happens, and the pharmacist makes the call.
Scheduling and registration status, read at the moment of supply.
The approval pathways and prescriber notifications your jurisdiction requires for unapproved and special-access medicines.
Eligibility criteria, restriction codes, and authority conditions for subsidised supply.
Controlled-substance schedules, and support for the record-keeping the most tightly controlled classes require.
Every dispense is a decision someone could later ask you to justify. This specialist tests each one against duty of care, professional and regulatory obligations, and the documentation standard a review would apply.
Each decision against the standard of care a review would apply.
Notes written to the evidentiary standard a professional review would apply.
The professional conduct and ethics requirements your registration board sets.
Where a decision carries elevated risk, and who it should go to next.
A correct dispense the patient does not understand is not a finished job. This specialist sets counselling to the patient's literacy and language, and points to the support services they are entitled to.
Instructions and side-effect warnings pitched at the patient's reading level.
Counselling and patient materials in the patient's own language.
Patients drifting off their medicine, early enough to do something about it.
Subsidy safety-net thresholds, and the public health, mental-health, aged-care and disability support pathways patients are entitled to.
Cultural safety for First Nations and culturally and linguistically diverse communities.
No extra screen, and no separate compliance step at the end of the month.